STARTUP PROFILE

Onward Medical

COUNTRY
Netherlands
FOUNDED
2014
CATEGORY
Neuromodulation
Developing implantable and non-invasive neuromodulation systems to restore movement and autonomic function after spinal cord injury.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Public
MODALITY
SCS
FORM FACTOR
External device
INTERFACE DEPTH
Non-invasive
INDICATION
Paralysis/motor
TARGET USER
Patients
REGULATORY STAGE
FDA cleared (510k)
Onward Medical is among the most advanced restorative neuromodulation companies, targeting movement and autonomic recovery after spinal cord injury using both implantable and non-invasive systems. Its public status and regulatory progress place it in the upper tier of neurorehabilitation platforms.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
9
BCI Shows its Value
1 September – 15 September 2026

ONWARD Medical performed the first implant in EIGER, a new feasibility study of its ARC-IM system for restoring mobility after spinal cord injury. The implanted device delivers targeted spinal cord stimulation to support standing and walking. EIGER is the first ONWARD mobility study to include people with subacute injuries, sustained within six weeks of the procedure. The procedure took place at Lausanne University Hospital under the supervision of co-founder Dr. Jocelyne Bloch.

Articles featuring
Onward Medical